Hong Kong—Aidigong Maternal & Child Health Limited (AIDIGONG) filed its Monthly Return for Equity Issuer for the period ended 31 August 2026, reporting no changes to either authorised or issued share capital during the month and affirming compliance with Hong Kong’s minimum 25% public-float requirement.
Authorised Capital • Ordinary shares: 2.00 billion at HKD 0.40 par value, representing HKD 800.00 million in authorised capital. • Convertible preference shares: 10.00 million Class A and 10.00 million Class B, each at HKD 0.40 par value, contributing HKD 8.00 million in aggregate. Total authorised share capital remained at HKD 808.00 million, unchanged from the prior month.
Issued Capital and Treasury Shares • Ordinary shares in issue stood at 192.18 million; no shares were issued, cancelled, or placed in treasury during August. • Treasury share balance remained nil, preserving the full count of issued shares. • The company confirmed that its public float exceeded the 25% threshold stipulated by Hong Kong listing rules.
Convertible Preference Shares • Outstanding Class A and Class B convertible preference shares were unchanged at 4.68 million each. • Conversion prices, previously adjusted following the July 2024 share consolidation and November 2024 placement, remain at HKD 12.64 (Class A) and HKD 17.43 (Class B). • No conversions into ordinary shares occurred during the month.
Equity Incentive Instruments • Share Option Scheme (approved 28 June 2022): 10.79 million options remain outstanding; no exercises recorded. • Incentive share agreement (approved 28 December 2020): authority to issue up to 1.25 million incentive shares remains unutilised. • Share Award Scheme (approved 30 August 2018): 1.59 million award shares remain available following adjustments linked to the July 2024 share consolidation; no new awards vested in August.
Net Share Movement Across all equity instruments—ordinary shares, preference shares, options, awards, and potential incentives—AIDIGONG reported zero net changes in issued or treasury shares for August 2026.
Regulatory Compliance The company affirmed that all securities-related activities during the month were duly authorised by the board and complied with Hong Kong listing rules and relevant regulatory requirements.